CME Presentations

Precision Medicine in Multiple Sclerosis


Presentations


Speakers

  • Jacquelyn Bainbridge, PharmD, FCCP

    Jacquelyn Bainbridge, PharmD, FCCP

    Jacquelyn Bainbridge, PharmD, FCCP

    Professor of Neurology, Department of Clinical Pharmacy

    Jacquelyn L. Bainbridge, BSPharm, PharmD, FCCP, MSCS, FAES, is a professor in the Department of Clinical Pharmacy and Neurology in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus in Aurora. Her research interests are in studying how antiepileptic drugs should be dosed in the older adult population. Dr Bainbridge is working on two CDPHE cannabis trials in back pain and Parkinson disease, and one study researching cannabidiol (CBD) in epilepsy. She has published several articles in professional journals, and reviewed and written multiple book chapters, including a few on multiple sclerosis and epilepsy. Dr Bainbridge is a member of numerous professional organizations, including the American Academy of Neurology.
  • Marijean Buhse, PhD, RN, NP-C, MSCN

    Marijean Buhse, PhD, RN, NP-C, MSCN

    Marijean Buhse, PhD, RN, NP-C, MSCN

    Clinical Professor

    Marijean Buhse, PhD, ANP, RN, MSCN, is a clinical professor and chair of the Advanced Practice Graduate Nursing Program in the School of Nursing at Stony Brook University in New York, and a nurse practitioner at South Shore Neurologic on Long Island. She has been an educator for 25 years and has cared for persons with multiple sclerosis (MS) for more than 18 years. Marijean has completed research and written journal articles on various aspects of living with MS. Much of her work focuses on the older person with MS and the effect on quality of life, social issues, and impact on caregivers. Marijean is a board member of the International Organization of MS Nurses and the Multiple Sclerosis Nurses International Certification Board, and past president of the Long Island MS Nurses Society.
  • Robert K. Shin, MD, FANA, FAAN

    Robert K. Shin, MD, FANA, FAAN

    Robert K. Shin, MD, FANA, FAAN

    Professor, Department of Neurology

    Robert K Shin, MD, FANA, FAAN, is a graduate of Yale University and received his medical degree from the University of Pennsylvania School of Medicine. He completed a neurology residency and fellowships in neuro-ophthalmology and multiple sclerosis at the Hospital of the University of Pennsylvania.

    Dr. Shin is currently Professor of Neurology at MedStar Georgetown University Hospital and Director of the Georgetown Multiple Sclerosis and Neuroimmunology Center. Dr. Shin has a special interest in visual problems associated with multiple sclerosis and other demyelinating disorders, including optic neuritis and double vision.
  • Daniel Ontaneda, MD, PhD

    Daniel Ontaneda, MD, PhD

    Daniel Ontaneda, MD, PhD

    Associate Professor of Neurology

    Daniel Ontaneda, MD, PhD, is associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and a staff member at the Cleveland Clinic Neurological Institute’s Mellen Center for Multiple Sclerosis (MS) in Ohio. He is the lead principal investigator for a large, international, multicenter study and the principal investigator for a central vein study in MS. Dr Ontaneda is a member of the Multiple Sclerosis Functional Composite Task Force. He was the recipient of a Sylvia Lawry NMSS Clinical Fellowship Award, NIH KL2 Cleveland CTSA career transition award. Dr Ontaneda received his medical degree from the Pontificia Universidad Católica del Ecuador and his doctoral degree in statistics and epidemiology at Case Western Reserve University.
  • Ellen Mowry, MD

    Ellen Mowry, MD

    Ellen Mowry, MD

    Professor of Neurology and Epidemiology

    Ellen Mowry, MD, is professor of neurology and epidemiology and co-director of the Johns Hopkins Multiple Sclerosis Precision Medicine Center of Excellence at Johns Hopkins University in Baltimore, Maryland. Her research focuses on environmental factors that influence the risk and prognosis of multiple sclerosis (MS), as well as on improving outcome measures for use in the clinic and in clinical trials. Dr Mowry is principal investigator (PI) or co-PI of several investigator-initiated randomized trials, including Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS), Altering the Timing or Amount of Calories in MS (ATAC-MS), and the TRaditional vs Early Aggressive Therapy for MS (TREAT-MS) trials. She received her medical degree from the University of Rochester in New York.

CME Information

Multiple Sclerosis Research to Practice II: High-Efficacy DMTs


CMSC Logo    PQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Summarize long-term outcomes of treatment with high-efficacy DMTs in patients with relapsing forms of MS
  • Identify for whom and when high-efficacy DMTs are appropriate in consideration of disease activity and patient factors
  • Apply research outcomes from registries and current clinical trials to identify and address patient needs with relapsing and progressive forms of MS
Jointly provided by Consortium of Multiple Sclerosis Centers and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by educational grants from Biogen, Genentech, and Sanofi Genzyme.

TUITION

No fee is required for this program

GENERAL CME/CNE/CE INFORMATION

In order to successfully complete this continuing education activity, the participant must register for the activity, attend the activity, and complete the online Evaluation and Claim for Credit form.

DATE OF RELEASE/EXPIRATION

Enduring Material

The enduring material will be available from September 14, 2020 to September 14, 2021

Target Audience

Neurologists, primary care physicians, advance practice clinicians, nursing professionals, pharmacists, and other healthcare professionals involved in the care of patients with MS.

Accreditation and Credit Information

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), and Platform Q Health Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this enduring material for a maximum of 1.0 Continuing Nursing Education Credits (1.0 credits in the area of pharmacology).

The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.0 contact hours (.1 CEUs) to pharmacists who complete the activity and complete the evaluation form. This is a knowledge-based activity.

The Universal Activity Number (UAN) for this enduring material is JA4008165-9999-20-044-H01-P.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/

Paper certificates are not valid for pharmacy credit.

Certificate of Completion

A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.

Disclosure of Unlabeled Use

CMSC and Platform Q Health Education require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

The faculty reported the following reference to unlabeled/unapproved use of drugs or products: Rituximab treatment for MS may be included in the discussion as well as ponesimod, ofatumumab (if not approved).

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

It is the policy of CMSC and Platform Q Health Education to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures

The faculty reported the following financial relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Ellen M. Mowry, MD served as faculty for this activity. She has received royalties for editorial duties from UpToDate. She has served as PI of IIT funded by Biogen; site PI of studies funded by Biogen. She has received free medication for clinical trial of which she is PI from Teva.
Daniel Ontaneda, MD, PhD served as faculty for this activity. He has received consulting fees from Genentech, Novartis, and Biogen.
June Halper, MSN, APN-C, MSCN, FAAN, served as planner and reviewer for this activity. She has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, served as nurse planner and reviewer for this activity. She has disclosed no relevant financial relationships.
All other CMSC and Platform Q Health Education staff who are in a position to influence content have disclosed no relevant financial relationships.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Contact Information

Accreditation Support:

Please contact the CMSC at education@mscare.org or 201-487-1050.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

Privacy Policy

Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/

Multiple Sclerosis Research to Practice I: Neuropathology and Biomarkers


CMSC Logo    PQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Summarize biomarkers in MS and their role in making treatment decisions
  • Examine how biomarkers may be associated with disease development and progression, differences in patient symptoms, and response to treatment
Jointly provided by Consortium of Multiple Sclerosis Centers and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by educational grants from Biogen, Genentech, and Sanofi Genzyme.

TUITION

No fee is required for this program

GENERAL CME/CNE/CE INFORMATION

In order to successfully complete this continuing education activity, the participant must register for the activity, attend the activity, and complete the online Evaluation and Claim for Credit form.

DATE OF RELEASE/EXPIRATION

Enduring Material

The enduring material will be available from September 14, 2020 to September 14, 2021

Target Audience

Neurologists, primary care physicians, advance practice clinicians, nursing professionals, pharmacists, and other healthcare professionals involved in the care of patients with MS.

Accreditation and Credit Information

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), and Platform Q Health Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this enduring material for a maximum of 1.0 Continuing Nursing Education Credits (1.0 credits in the area of pharmacology).

The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.0 contact hours (.1 CEUs) to pharmacists who complete the activity and complete the evaluation form. This is a knowledge-based activity.

The Universal Activity Number (UAN) for this enduring material is JA4008165-9999-20-042-H01-P.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/

Paper certificates are not valid for pharmacy credit.

Certificate of Completion

A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.

Disclosure of Unlabeled Use

CMSC and Platform Q Health Education require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

The faculty reported the following reference to unlabeled/unapproved use of drugs or products: Rituximab treatment for MS may be included in the discussion as well as ponesimod, ofatumumab (if not approved).

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

It is the policy of CMSC and Platform Q Health Education to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures

The faculty reported the following financial relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Ellen M. Mowry, MD served as faculty for this activity. She has received royalties for editorial duties from UpToDate. She has served as PI of IIT funded by Biogen; site PI of studies funded by Biogen. She has received free medication for clinical trial of which she is PI from Teva.
Daniel Ontaneda, MD, PhD served as faculty for this activity. He has received consulting fees from Genentech, Novartis, and Biogen.
June Halper, MSN, APN-C, MSCN, FAAN, served as planner and reviewer for this activity. She has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, served as nurse planner and reviewer for this activity. She has disclosed no relevant financial relationships.
All other CMSC and Platform Q Health Education staff who are in a position to influence content have disclosed no relevant financial relationships.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Contact Information

Accreditation Support:

Please contact the CMSC at education@mscare.org or 201-487-1050.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

Privacy Policy

Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/

Precision Medicine with Polypharmacy in Multiple Sclerosis: What does it mean in practice?


CMSC Logo    PQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Summarize approaches to providing personalized medicine for MS diagnosis and management while minimizing drug interactions with medications for common comorbidities
  • Appraise current data on biomarkers for differentiating MS from other disorders and MS phenotypes
  • Evaluate algorithms and predictive models for MS management
Jointly provided by Consortium of Multiple Sclerosis Centers and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by educational grants from Biogen, Genentech, and Sanofi Genzyme.

TUITION

Complimentary

GENERAL CME/CNE/CE INFORMATION

In order to successfully complete this continuing education activity, the participant must register for the activity, attend the activity, and complete the online Evaluation and Claim for Credit form.

DATE OF RELEASE/EXPIRATION

Enduring Material

Precision Medicine with Polypharmacy in Multiple Sclerosis: What does it mean in practice?
The enduring material will be available from July 15, 2020 to September 14, 2021

Target Audience

Neurologists, primary care physicians, advance practice clinicians, nursing professionals, pharmacists, and other HCPs involved in the care of patients with MS.

Accreditation and Credit Information

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), and Platform Q Health Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this enduring material for a maximum of 1.0 Continuing Nursing Education Credits (0 credits in the area of pharmacology).

The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.0 contact hours (.1 CEUs) to pharmacists who (1) complete the activity, (2) submit a passing post-test, and (3) complete the evaluation form. This is a knowledge-based activity.

The Universal Activity Number (UAN) for this enduring material is JA4008165-9999-20-032-H01-P.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Paper certificates are not valid for pharmacy credit.

Certificate of Completion

A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.

Disclosure of Unlabeled Use

CMSC and Platform Q Health Education require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. The faculty reported the following reference to unlabeled/unapproved use of drugs or products: Rituximab may be included in the discussion, as well as ponesimod and ofatumumab (if not approved).

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the activity front matter, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

It is the policy of CMSC and Platform Q Health Education to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

Faculty Disclosures

The faculty reported the following financial relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Jacquelyn L. Bainbridge, PharmD, FCCP, MSCS, FAES served as faculty for this activity. She has served on an advisory board for Genentech.

Marijean Buhse, PhD, RN, NP-C, MSCN served as faculty for this activity. She has received consulting fees from Biogen and Genzyme. She has served on the speaker’s bureau for Biogen and Genzyme.

Robert K. Shin, MD, FANA, FAAN served as faculty for this activity. He has received consulting fees from Biogen, Bristol Myers Squibb, EMD Serono, Mallinckrodt, Novartis, and Sanofi Genzyme. He has served on the speaker’s bureau for Biogen, Bristol Myers Squibb, EMD Serono, Mallinckrodt, Novartis, and Sanofi Genzyme.

June Halper, MSN, APN-C, MSCN, FAAN, served as planner and reviewer for this activity. She has disclosed no relevant financial relationships.

Laurie Scudder, DNP, NP, served as nurse planner and reviewer for this activity. She has disclosed no relevant financial relationships.

All other CMSC and Platform Q Health Education staff who are in a position to influence content have disclosed no relevant financial relationships.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Contact Information

Accreditation Support:

Please contact the CMSC at education@mscare.org or 201-487-1050.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

Privacy Policy

Please review our privacy policy here: https://www.neuroserieslive.com/privacy-policy/